Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes ...

REBLOZYL ® is the first and only erythroid maturation agent approved for use in Canada MONTREAL, Sept. 29, 2020 /CNW/ - Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today ...

SUMMIT, N.J.& CAMBRIDGE, Mass.---- Celgene Corporation and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration has approved REBLOZYL ® for the treatment of anemia in adult ...

Reblozyl is also approved for the treatment of anemia in adults with beta thalassemia who require RBC transfusions; and for the treatment of anemia failing an ESA and requiring 2 or more RBC units ...